| Title |
Golimumab for the treatment of ulcerative colitis
|
|---|---|
| Published in |
Clinical and Experimental Gastroenterology, March 2014
|
| DOI | 10.2147/ceg.s48741 |
| Pubmed ID | |
| Authors |
Mark Löwenberg, Nanne KH de Boer, Frank Hoentjen |
| Abstract |
The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. However, a proportion of UC patients for whom therapy with anti-TNF agents is indicated fail or become intolerant to treatment with infliximab or adalimumab. Hence, there remains an unmet need for novel anti-TNF agents. Golimumab (Simponi®), a human anti-TNF antibody that is administered by monthly subcutaneous injections, is the most recently introduced TNF blocker for the treatment of UC. Here, we will discuss recent literature on clinical efficacy and safety of golimumab induction and maintenance treatment in patients with UC. Furthermore, we will discuss the positioning of golimumab for UC in current treatment algorithms. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 2% |
| Unknown | 60 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 16% |
| Student > Master | 8 | 13% |
| Student > Bachelor | 8 | 13% |
| Student > Ph. D. Student | 7 | 11% |
| Student > Postgraduate | 6 | 10% |
| Other | 12 | 20% |
| Unknown | 10 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 51% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 10% |
| Agricultural and Biological Sciences | 3 | 5% |
| Computer Science | 2 | 3% |
| Social Sciences | 2 | 3% |
| Other | 5 | 8% |
| Unknown | 12 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 October 2023.
All research outputs
#5,340,716
of 25,584,565 outputs
Outputs from Clinical and Experimental Gastroenterology
#79
of 311 outputs
Outputs of similar age
#48,840
of 236,752 outputs
Outputs of similar age from Clinical and Experimental Gastroenterology
#2
of 4 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 311 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 10.0. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 236,752 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.